Bayer Corporation

08/05/2022 | Press release | Distributed by Public on 08/05/2022 17:22

U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)